Search Results
Oct 07, 2025, 11:51 ET WaveBreak Presents Human Brain Tissue Data Demonstrating Binding and Efficacy of Small Molecule WTX-607 Against Alpha-Synuclein Aggregates for Parkinson's Disease and Lewy Body Dementia
inhibiting α-synuclein aggregation seeded from patient brain tissue at therapeutically relevant drug concentrations," said co-investigator Kelvin Luk, PhD, Associate Professor of Pathology and Laboratory Medicine at the Perelman School of Medicine, University of Pennsylvania and a Scientific Advisor of
More news about: WaveBreak
Oct 07, 2025, 11:00 ET Inaugural Showcase from the Oberkotter Foundation to Feature Literacy Efforts in Georgia
barriers, raise awareness, increase access to care, and create new opportunities for children who are deaf or hard of hearing," says Teresa Caraway, PhD, CCC-SLP, LSLS Cert. AVT, CEO, Oberkotter Foundation. "The Showcase Series aims to break down the silos and create a knowledge exchange between the committed
More news about: Oberkotter Foundation
Oct 07, 2025, 09:30 ET MONTEFIORE CELEBRATES OPENING OF NEW WIC PROGRAM LOCATION TO SUPPORT NUTRITIONAL NEEDS OF BRONX MOMS & BABIES
"The need for nutrition services, education and strong ties to social support are increasing every year," said Carmen Nauta, PhD, IBCLC, RLC, WIC Coordinator, Montefiore Medical Group. "We are extremely grateful for the investment New York State is making to help our families experiencing
More news about: Montefiore Health System
Oct 07, 2025, 09:30 ET MONTEFIORE CELEBRA LA INAUGURACIÓN DE UN NUEVO CENTRO DEL PROGRAMA WIC PARA SATISFACER LAS NECESIDADES NUTRICIONALES DE MADRES Y BEBÉS DEL BRONX
"La necesidad de servicios nutricionales, educación y vínculos sólidos con la red de apoyo social aumenta cada año", dice Carmen Nauta, PhD, IBCLC, RLC, Coordinadora del Programa WIC de Montefiore Medical Group. "Estamos muy agradecidos por la inversión que está realizando el estado de Nueva
More news about: Montefiore Health System
Oct 07, 2025, 09:07 ET Sellers Remember 50% More with AI--But Thrive with Human Feedback
experience. I was especially impressed by Dr. Carmen Simon's expertise, which added so much depth to the findings. As someone currently working on my own PhD dissertation, I found it inspiring to learn from Dr. Simon and to see academic research translated into real-world business impact. The results reinforced
More news about: Allego
Oct 07, 2025, 09:07 ET Sellers Remember 50% More with AI--But Thrive with Human Feedback
experience. I was especially impressed by Dr. Carmen Simon's expertise, which added so much depth to the findings. As someone currently working on my own PhD dissertation, I found it inspiring to learn from Dr. Simon and to see academic research translated into real-world business impact. The results reinforced
More news about: Allego
Oct 07, 2025, 09:00 ET Helix to Present New Population-Scale Genomic Research at ASHG 2025 Annual Meeting
Cirulli, PhD, Associate Director, Research Using statistical associations from clinicogenomic datasets to resolve VUSWednesday, October 15, from 2:30 - 4:30 p.m. ET in the Main Poster Area (2055W)Presented by Matt Ferber, PhD, Senior Staff
More news about: Helix
Oct 07, 2025, 09:00 ET Introducing Benchling AI
Omar Abudayyeh PhD, Assistant Professor at Harvard Medical School, Abudayyeh-Gootenberg Lab. "We're no longer limited by what any single scientist can remember — we're
More news about: Benchling
Oct 07, 2025, 09:00 ET University of Mississippi School of Law Launches Nation's First Online Master of Science in Air and Space Law
that helps students not only acquire specialized legal knowledge, but also retain and apply it in real-world aerospace contexts," said Whitney Kilgore, PhD, co-founder and Chief Academic Officer of iDesign. "Grounded in the science of how people learn, the curriculum leverages evidence-based instructional
More news about: idesignedu.org
Oct 07, 2025, 09:00 ET Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
is not the outcome we had hoped for, we respect FDA's feedback and remain confident in the therapeutic potential of Cylembio," said Mai-Britt Zocca, PhD, CEO of IO Biotech. "We look forward to continuing the dialogue with FDA to align on the design for a potential new registrational study. Additionally,
More news about: USA News Group
Oct 07, 2025, 08:36 ET HeartX Cardiovascular Accelerator Announces Seven Startup Companies Selected for the 2025 Program
value for our cohort companies." "The 2025 HeartX cohort represents the next wave of healthcare trailblazers," said Joe Sasson, PhD, MedAxiom's chief commercial officer and executive vice president of Ventures. "By pairing bold cardiovascular innovations with the realities of clinical
More news about: HeartX
Oct 07, 2025, 08:35 ET The Alliance to Stop Foodborne Illness Announces 40 Food Safety Professionals Under 40, Class of 2025
outstanding leaders in food safety, we continue to be inspired by the passion and achievements reflected in this year's applications," said Vanessa Coffman, PhD, Alliance Director at Stop Foodborne Illness. "Foodborne illness remains a serious challenge, but the future is bright thanks to the collaboration, innovation,
More news about: The Alliance to Stop Foodborne Illness
Oct 07, 2025, 08:33 ET Biotech and Veterinary Innovators Dr. Misti Ushio and Doug Drew Join Gallant Board of Directors
Gallant, an animal health biotechnology company pioneering ready-to-use stem cell therapies for pets, today announced the addition of Misti Ushio, PhD, and Doug Drew, MBA, to its Board of Directors. Together, they bring decades of experience in biotech innovation, the commercialization of new therapeutic
More news about: Gallant
Oct 07, 2025, 08:30 ET The Value Proposition of Specialty CROs, Upcoming Webinar Hosted by Xtalks
Join Gary Zammit, PhD, Founder, President, CEO, Clinilabs; Colin Orford, PhD, Therapeutic Lead, Psychiatry, Clinilabs;
More news about: Xtalks
Oct 07, 2025, 08:05 ET TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis
advancing the science that delivers both meaningful outcomes and more choices for healthcare providers and their patients," said Esi Lamousé-Smith, MD, PhD, Vice President, Gastroenterology Disease Area Lead, Immunology, Johnson & Johnson Innovative Medicine. "TREMFYA is the only IL-23 inhibitor to offer
More news about: Johnson & Johnson
Oct 07, 2025, 08:00 ET Majority of Americans Say Losing Mobility Is Their Top Aging Concern - APTA Launches Campaign to Promote Health Span Longevity Through Lifelong Movement
prevent injury, support lifelong mobility, and improve overall health for people of all ages and abilities," said APTA President Kyle Covington, PT, DPT, PhD. "With the 'PT For Future Me campaign,' we want to shift the mindset from seeing physical therapy as only a treatment for injury or surgical recovery
More news about: American Physical Therapy Association
Oct 07, 2025, 08:00 ET Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
our confidence in its potential to be a best-in-class Claudin 18.2-directed therapy for metastatic gastric cancers in the 1L setting," said Sean Fu, PhD, CEO of I-Mab. "Based on these accomplishments, we are expanding our investment in givastomig, with plans to initiate a randomized Phase 2 study
More news about: Equity Insider
Oct 07, 2025, 07:37 ET Brain Stimulation May Reduce Cannabis Addiction in People with Multiple Sclerosis
a safe, portable option that people with cannabis use disorder can use daily to support their recovery," said study lead author Giuseppina Pilloni, PhD, an assistant professor in the Department of Neurology at NYU Grossman School of Medicine. Pilloni notes that there are currently
More news about: NYU Grossman School of Medicine and NYU Langone Health
Oct 07, 2025, 07:30 ET Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
have reached this important milestone, confirming the expected safety to date in the confirmatory FLASH2 study," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "As patient enrollment continues to track with our initial estimates, we anticipate providing an
More news about: SOLIGENIX, INC.
Oct 07, 2025, 07:15 ET LEVY Health Partners with IVF Academy USA to Support OB-GYN Training in Fertility Medicine
"Supporting physicians in their transition to fertility medicine is at the heart of IVF Academy USA's mission," said Paul Magarelli, MD, PhD, dean of the clinical school at IVF Academy USA. "Through our collaboration with LEVY Health, we ensure that trainees have access to up-to-date medical
More news about: Levy Health USA, Inc.
Oct 07, 2025, 07:00 ET TORL BioTherapeutics Secures $96M Series C Financing and Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2025 European Society of Medical Oncology Congress
ovarian cancer, a defined subset of the disease with particularly poor prognosis," said Scientific Co-founder and Board Member Dennis Slamon, MD, PhD, Professor of Medicine, and Chief of the Division of Hematology/Oncology at UCLA's David Geffen School of Medicine. "TORL-1-23 is the first of multiple
More news about: TORL Biotherapeutics LLC
Oct 07, 2025, 06:58 ET Tech Basel Miami AI Summit To Ignite Next Wave of Innovation
Patel is known for making complex AI concepts clear and actionable, speaking on generative AI, the future of LLMs and AI's business impact. He holds a PhD in Game Theory from Northwestern and is the author of the widely shared article "Understanding LLMs from Scratch." Currently building the company's
More news about: eMerge Americas
Oct 07, 2025, 06:10 ET Ryght AI Assembles Renowned Medical Leaders to Guide Next Phase of Clinical Trial AI Innovation
Vivek Subbiah, MDChief, Early-Phase Drug Development, Sarah Cannon Research institute Greg Vidal, MD, PhD Director of Clinical Research and Lead of the Breast Cancer Program, West Cancer Center and Research Institute
More news about: Ryght
Oct 07, 2025, 06:00 ET InsightRX Achieves 96.1 Performance Score in KLAS Spotlight as the First Precision Dosing AI Solution
Sirj Goswami, PhD, CEO and Co-Founder of InsightRX. "Our vision is to expand precision dosing to new drug classes and therapeutic areas, while building the foundation
More news about: InsightRX
Oct 07, 2025, 06:00 ET Invisible Wounds Foundation Names Nationally Recognized Brain Health Experts to its Board of Directors, Medical and Science Advisory Council
science experts on our MSAC, I am confident that we will accelerate the discovery of solutions to address TBI for our warfighters," said Shannon Connell, PhD, CEO of the Invisible Wounds Foundation. About the Invisible Wounds Foundation
More news about: Invisible Wounds Foundation